Slingshot members are tracking this event:

Fitusiran (ALN-AT3) Phase 1 Open Label Extension study initial data expected in late 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Update on 7.25.16: Alnylam plans to report additional data from fitusiran studies in late 2016. These data are expected to include additional results from Part D of the ongoing Phase 1 study and initial results from the Phase 1/2 open-label extension (OLE) study. 
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 03, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Fitusiran, Aln-at3, Antithrombin, Hemophilia, Rare Bleeding Disorders, Phase 1, Open Label Extension